Oncotarget cover image

Oncotarget

Latest episodes

undefined
Sep 29, 2022 • 3min

Press Release: HIV/HPV-Related Metastatic Colorectal Cancer Response to Nivolumab

Exploring challenges in predicting Nivolumab response in an HIV-positive anal cancer patient with MSI, emphasizing molecular analysis for tailored treatment decisions.
undefined
Sep 28, 2022 • 7min

How High Altitudes Influence HIF-1, Gastric Cancer & Patient Survival

High altitudes influence various physiological processes like HIF-1 expression and vitamin D levels, impacting diseases like gastric cancer. GA incidence is higher at high altitudes due to hypoxia-induced HIF-1 activation. Understanding the role of HIF-1 in GA pathogenesis and prognosis is crucial for high-altitude populations.
undefined
Sep 26, 2022 • 6min

Trending With Impact: Protein-Based Risk Model Predicts Esophageal Cancer Recurrence

Exploring the protein-based risk model for esophageal cancer recurrence, researchers identify biomarkers to improve treatment outcomes. Four prognostic molecular signatures show promise in predicting disease recurrence and stratifying patients based on risk levels.
undefined
Sep 20, 2022 • 4min

Press Release: Targeting RCC w/Poly ADP-ribose Polymerase Inhibitors, Low-dose Alkylating Chemo

New research paper explores targeting Krebs-cycle-deficient renal cell carcinoma with PARP inhibitors and low-dose alkylating chemo. Loss-of-function mutations in FH and SDH genes induce cancer syndromes. Fumarate and succinate inhibit DNA repair pathway, leading to accumulation of DNA double-strand breaks. Researchers develop murine models demonstrating alterations in transcriptomic and methylation profile.
undefined
Sep 19, 2022 • 9min

Behind the Study: Inhibition of Resistant Triple-negative Breast Cancer Cells

Dr. Balraj Singh, a researcher from The University of Texas MD Anderson Cancer Center, discusses inhibiting resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. They explore the efficacy of these drugs and their potential to overcome chemotherapy resistance. The podcast also delves into the use of 6MP in enhancing immune checkpoint blockage for combating autoimmunity and cancer cells.
undefined
Sep 15, 2022 • 4min

Press Release: An ABC Transporter as a Potential Target Against SHH-Medulloblastoma

Researchers from St. Jude Children’s Research Hospital discuss the challenges of treating SHH-Medulloblastoma in young children through standard methods such as radiation therapy and SMO inhibitors. They highlight the need for novel therapeutic approaches and explore the potential of an ABC transporter as a new target for treatment.
undefined
Sep 12, 2022 • 8min

Behind the Study: Targeting Lipid Metabolism in Treatment of Ovarian Cancer

Researchers Dr. Glenn Simmons Jr. and Dr. Stefani Thomas discuss targeting lipid metabolism in ovarian cancer treatment. They highlight the role of unsaturated fatty acids in cancer cell growth, chemotherapy resistance, and immune response evasion. The podcast explores challenges in current therapies and the use of mass spectrometry to identify potential targets for more effective treatments.
undefined
Sep 8, 2022 • 5min

Press Release: Imaging With Polypeptide Fusion Protein Targets Bladder Cancer

Discover the development of a targeted imaging probe for detecting bladder cancer using polypeptide fusion proteins. Learn about the high sensitivity and selectivity of a NIR probe in labeling tumor tissue, showcasing potential for clinical translation and patient imaging.
undefined
Sep 1, 2022 • 7min

Immunotherapy Response Predicted By Machine Learning & Gut Microbiomes

Exploring how machine learning is used to predict immunotherapy response with a focus on gut microbiomes. Studying the impact of gut microbiomes on the immune system and their potential as a biomarker. Analyzing the predictive potential of gut microbiomes in immunotherapy response and the significance of machine learning in understanding microbiome-immunotherapy interactions.
undefined
Aug 24, 2022 • 7min

Epigenetics and Immunotherapy Combined Fights Rare Lymphoma

Exploring the synergistic effects of epigenetic and immunotherapy treatments in managing aggressive blastic mantle cell lymphoma, a challenging subtype of non-Hodgkin’s lymphoma, with high recurrence rates and poor treatment outcomes. Researchers discuss potential breakthroughs in offering improved survival rates and long-term remissions through a combination of treatment modalities, paving the way for future research on predictive biomarkers.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner